NCT04836858 - A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 20, 2021

Primary Completion Date

July 14, 2022

Study Completion Date

December 13, 2022

Conditions

Atopic Dermatitis

Interventions

BIOLOGICAL

CMK389

Active

BIOLOGICAL

Placebo

Placebo Comparator

Trial Locations (18)

1085

Novartis Investigative Site, Budapest

6720

Novartis Investigative Site, Szeged

10117

Novartis Investigative Site, Berlin

13008

Novartis Investigative Site, Marseille

14004

Novartis Investigative Site, Córdoba

48149

Novartis Investigative Site, Münster

48455

Novartis Investigative Site, Bad Bentheim

49074

Novartis Investigative Site, Osnabrück

60596

Novartis Investigative Site, Frankfurt

69120

Novartis Investigative Site, Heidelberg

76031

Novartis Investigative Site, Rouen

81377

Novartis Investigative Site, München

530 02

Novartis Investigative Site, Pardubice

100 34

Novartis Investigative Site, Prague

06202

Novartis Investigative Site, Nice

80-546

Novartis Investigative Site, Gdansk

90-265

Novartis Investigative Site, Lodz

35 055

Novartis Investigative Site, Rzeszów